Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

by Tithi Biswas, Kylie H. Kang, Rohin Gawdi, David Bajor, Mitchell Machtay, Charu Jindal, Jimmy T. Efird
Published 2020-10-01